Artiflex por. d/or. solution 1.5/4g No. 20 - Instructions

Instructions for use

pharmachologic effect

Artiflex reduces inflammation, relieves pain, and gradually restores damaged areas of the joint. In the process of its use, neutralization of the action of free radicals and inhibition of pathological enzymatic processes occurring in the body is observed.

The therapeutic effect of the drug is cumulative: if classical NSAIDs begin to act immediately, then Artiflex - after 2 weeks of constant use.

The advantage of the drug is that it eliminates the cause of discomfort and regenerates cartilage tissue, which other NSAIDs do not do. It is noteworthy that clinical improvement persists for 2 months after discontinuation of the drug.

A distinctive feature of NSAIDs Artiflex is the ability to restore cartilage tissue

The active component of Artiflex is glucosamine sulfate..

This substance is synthesized in animals and humans and performs important biological functions:

• participates in the formation of enzymes and hormones;
• gives elasticity to cartilage, provides cushioning for joints;
• improves the functioning of local immunity.

Glucosamine is part of the synovial fluid that fills the joint cavity, protecting it from premature wear and friction. In degenerative and inflammatory processes, there is a deficiency of glucosamine, which leads to pain, loss of elasticity of the cartilage tissue of the joints and its destruction.

Artiflex stops destructive processes, stimulates the production of intra-articular fluid and chondroitinsulfuric acids, restores the elasticity of joints and increases their level of mobility, ensures normal deposition of bone calcium, and relieves pain. The drug does not have a negative effect on the respiratory, nervous and cardiovascular systems of the body.

Indications for use

Artiflex should only be prescribed by a specialist. The use of the drug is possible in the presence of degenerative and dystrophic processes occurring in the area of ​​peripheral joints or directly in the vertebrae . In particular, the medicine can be prescribed for osteoarthritis and its symptoms (functional limitations, pain).

Artiflex is recommended for those who suffer from degenerative pathologies of the musculoskeletal system.

The drug in the form of a cream is prescribed to patients with diseases of the musculoskeletal system , accompanied by swelling, pain, signs of inflammation, degenerative changes in cartilage tissue, and decreased joint mobility. Such diseases include osteoarthritis, intervertebral osteochondrosis, and arthropathy.

Directions for use, dosage

The drug in powder form is used orally (inside) . To do this, the contents of 1 packet are dissolved in a glass of water and drunk during meals. Adults and elderly patients are recommended to take 1 sachet per day. The duration of therapy varies from 4 to 12 weeks. If necessary, the course can be extended, but this can only be done with the permission of the doctor.

It is advisable to take Artiflex in courses, as this allows you to achieve maximum effect. If the doctor allows, you can repeat the therapy 2 or 3 times a year. The intervals between courses should be 2 months.

As for the cream, it should be applied 2-3 times a day . The drug is applied to the skin in the area of ​​the damaged joint and rubbed until completely absorbed with light massage movements. The duration of such treatment is 14 days.

Release form, composition

Classic Artiflex is produced in the form of a powder for oral use and a cream for topical use . The powder is sold in sachets placed in cardboard packaging. The active component of the drug is glucosamine sulfate .

The cream is sold in tubes of 20 and 40 g. It has a white color and a specific smell. The active components of the cream are glucosamine hydrochloride, allantoin, ibuprofen.

The auxiliary components are glycerin monostearate, isopropyl myristate, polyethylene glycol stearate, ethanol 96%, propylparaben, methylpyrolidinone, purified water, mineral oil, cetostearyl alcohol, polysorbate 80, methylparaben, menthol, sodium metabisulfite.

Video: “Overview of the appearance of the drug Artiflex Plus”

Interaction with other drugs

The medicine is compatible with GCS and NSAIDs.

When used in parallel, the effect of coumarin anticoagulants is enhanced. Therefore, patients are advised to keep coagulation parameters under control.

With simultaneous use of Artiflex and tetracycline, the gastrointestinal absorption of the latter may increase.

Pharmacological properties of the drug Artiflex

Artiflex is a drug that affects metabolism in cartilage tissue. Glucosamine sulfate is a salt of the natural aminomonosaccharide glucosamine with low molecular weight, carefully purified from macromolecular components. The drug replenishes the endogenous deficiency of glucosamine and stimulates the synthesis of hyaluronic acid proteoglycans in synovial fluid. Increases the permeability of the joint capsule, restores enzymatic processes in the cells of the synovial membrane and articular cartilage. The anti-inflammatory effect of glucosamine sulfate is due to blocking the formation of superoxide radicals by macrophages and inhibition of lysosomal enzymes. The drug promotes the fixation of sulfur in the process of chondroitinsulfuric acid synthesis, facilitates the absorption of calcium in bone tissue, inhibits the development of degenerative processes in the joints, restores their function, reducing the severity of joint pain. Sulfates are also involved in the synthesis of glycosaminoglycans and the metabolism of cartilage tissue. The sulfate ester side chains of proteoglycans are important for maintaining the elasticity and water retention capacity of the cartilage matrix. The severity of clinical symptoms usually decreases 2 weeks after the start of treatment, with the effect maintaining for 8 weeks after discontinuation of the drug. Pharmacokinetics. Glucosamine sulfate is quickly and completely absorbed in the small intestine (90%). Easily passes through biological barriers and penetrates tissue, mainly articular cartilage. T½ - 68 hours.

Side effects

The use of Artiflex can lead to the development of undesirable reactions from various systems and organs.

Possible side effects are described below:

Undesirable reactions of the body to Artiflex should be observed and monitored by a doctor.

Overdose

Did you know that...

Next fact

There have been no cases of overdose in clinical practice. It was found that the drug is not toxic even at significantly higher doses . If an accidental overdose occurs, the patient's stomach is washed and symptomatic treatment is prescribed.

Contraindications

The drug is contraindicated in case of individual intolerance to glucasamine sulfate. The powder is not allowed to be used if:

• phenylketonuria;
• treatment of children;
• individual intolerance to glucosamine sulfate and other drug components;
• treatment of lactating and pregnant women.

The cream is not prescribed for dermatoses, weeping eczema, asthma, or hypersensitivity to the components of Artiflex. Also, the use of the medicine is prohibited if the use of NSAIDs can cause an asthmatic attack in the patient.

To obtain glucosamine, shellfish shells are used, which should be taken into account in patients with allergies to shellfish (Artiflex should be used with caution).

The powder for oral administration contains sorbitol, so patients with a rare hereditary form of fructose intolerance should not be prescribed Artiflex in powder.

If the patient suffers from severe renal or liver failure, the medicine should be prescribed under the supervision of a doctor. For concomitant renal diseases, the medicine is used with caution.

During pregnancy

Breastfeeding and pregnancy are absolute contraindications to the use of Artiflex.

Artiflex por. d/or. solution 1.5/4g No. 20 - Instructions

DOSAGE FORM

Powder for oral solution, 4 g in bags No. 20 per box.

COMPOUND

Active ingredient: glucosamine;

1 package contains glucosamine sulfate sodium chloride 1.884 g (equivalent to 1.5 g glucosamine sulfate and 0.384 g sodium chloride).

Excipients: sorbitol (E 420), citric acid, aspartame (E 951), polyethylene glycol 4000.

PHARMACOLOGICAL GROUP

Nonsteroidal anti-inflammatory and antirheumatic drugs.

PHARMACOLOGICAL PROPERTIES

Pharmacological. The active ingredient is a salt of the aminomonosaccharide glucosamine sulfate, which is present in the human body and is used together with sulfates for the biosynthesis of hyaluronic acid in synovial fluid and glycosaminoglycans of the main substance of articular cartilage.

The mechanism of action of glucosamine sulfate is stimulation of the synthesis of glycosaminoglycans and, accordingly, articular proteoglycans. In addition, glucosamine exhibits anti-inflammatory properties, slows down the destruction of articular cartilage mainly due to its metabolic activities, the ability to suppress the activity of interleukin 1 (IL-1), which, on the one hand, contributes to the effects on the symptoms of osteoarthritis, and on the other hand, the delay of structural joint disorders, as evidenced by data from long-term clinical studies.

The effectiveness of glucosamine sulfate regarding osteoarthritis is obvious within 2-3 weeks from the start of treatment.

There are data from clinical studies of daily continuous treatment for 3 years, indicating a progressive increase in the effectiveness of glucosamine sulfate, taking into account symptoms and slowing structural damage to the joints, confirmed by x-ray.

Glucosamine sulfate demonstrated good tolerability. No significant effects of glucosamine sulfate on the cardiovascular, respiratory, autonomic or central nervous system were found.

Pharmacokinetics. 90% of the dose of glucosamine sulfate is quickly and completely absorbed from the gastrointestinal tract, passes through biological barriers and penetrates tissue, mainly articular cartilage. Bioavailability - 26%. T ½ - 68 hours.

INDICATIONS FOR USE

Treatment of symptoms of osteoarthritis, i.e. pain and functional limitation.

METHOD OF APPLICATION AND DOSES

Apply internally.

For adult and elderly patients, dissolve the contents of one packet, equivalent to 1.5 g of glucosamine sulfate, in a glass of water and take 1 time per day, preferably with meals.

The course of treatment is 4-12 weeks or longer (if necessary). As prescribed by the doctor, treatment can be repeated 2-3 times a year with an interval of 2 months, as well as in case of relapse of the disease.

CONTRAINDICATIONS

Hypersensitivity to the components of the drug. Impaired liver and kidney functions in the stage of decompensation, tendency to bleeding. Phenylketonuria. Allergy to shellfish (the active substance is obtained from shellfish).

INTERACTIONS WITH OTHER MEDICINES AND OTHER TYPES OF INTERACTIONS

An increase in the effect of coumarin anticoagulants was noted. In this regard, it is advisable for patients to monitor coagulation parameters.

It is possible to enhance the gastrointestinal absorption of tetracycline.

The drug is compatible with non-steroidal anti-inflammatory drugs and glucocorticosteroids.

APPLICATION FEATURES

In patients with bronchial asthma, the drug should be used with caution, since such patients may be more prone to developing allergic reactions to glucosamine with a possible exacerbation of the symptoms of their disease.

The drug contains sorbitol, therefore, patients who have a rare hereditary form of fructose intolerance are not recommended to use the drug in this dosage form.

Patients on a sodium-controlled diet should be aware of the amount of sodium in this dosage form (151 mg per packet).

At the beginning of treatment for patients with diabetes, it is advisable to monitor blood sugar levels.

Use only under medical supervision in patients with impaired liver and kidney function (except for disorders in the stage of decompensation), with thrombophlebitis.

USE DURING PREGNANCY OR BREAST-FEEDING

There are no data on the use of the drug during pregnancy and lactation, therefore use during this period is contraindicated.

ABILITY TO INFLUENCE REACTION SPEED WHEN DRIVING VEHICLES OR OTHER MECHANISMS

Studies on the effect of the drug on the ability to drive a car or use other machinery have not been conducted. Caution should be exercised when operating vehicles or performing work that requires attention. In case of drowsiness, fatigue, dizziness or visual impairment, driving or operating machinery is prohibited.

CHILDREN

Do not use in children, since the safety and effectiveness of the drug for such patients have not been established.

OVERDOSE

There were no cases of overdose. Existing data from acute and chronic toxicity studies in animals indicate that toxic symptoms are unlikely to occur even at doses up to 200 times the therapeutic dose. However, with an overdose, the manifestations of adverse reactions may increase, so it is worthwhile to carry out symptomatic treatment aimed at restoring water and electrolyte balance.

ADVERSE REACTIONS

From the digestive system: abdominal pain, flatulence, dyspepsia, diarrhea, constipation, nausea.

From the nervous system: headache, drowsiness, fatigue, dizziness.

From the immune system: allergic reactions.

From the organ of vision: visual impairment.

Skin: erythema, itching, rash, angioedema, urticaria, hair loss.

BEST BEFORE DATE

3 years.

STORAGE CONDITIONS

Store in original packaging at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

VACATION CATEGORY

On prescription.

special instructions

Exceeding the recommended doses and duration of treatment is prohibited . Long-term use of the drug may lead to the development of side effects.

If the patient suffers from diabetes, blood glucose levels should be monitored at the beginning of therapy.

People following a sodium-controlled diet should be aware that the oral dosage form contains sodium (151 mg per daily dose).

The cream should not be applied to open wounds. It is important to ensure that the drug does not get on the mucous membranes.

Impact on the ability to operate machinery and drive vehicles

Artiflex does not affect the ability to operate machinery, including transport.

Use in pediatrics

Artiflex powder is not prescribed to children. The cream can be used in pediatrics if the patient has reached 12 years of age.

For impaired renal function

For people with severe renal failure, the medication is prescribed exclusively under the supervision of a doctor.

For liver dysfunction

For persons with severe liver failure, Artiflex can be prescribed only with the permission of a doctor.

Conditions for dispensing from pharmacies

You can purchase the medicine at any pharmacy without a prescription.

Video: “Overview and description of the drug Artiflex Ultra”

Artiflex ultra, capsules No. 60 - Instructions

DOSAGE FORM

Capsules in a package of 60 pieces.

COMPOUND

Active ingredients: glucosamine, chondroitin sulfate, ibuprofen;

1 capsule contains glucosamine sulfate sodium chloride in terms of glucosamine sulfate 250 mg, sodium chondroitin sulfate 200 mg, ibuprofen 100 mg.

Excipients: corn starch, crospovidone, sodium starch (type A), stearic acid, microcrystalline cellulose, magnesium stearate, povidone, colloidal silicon dioxide; capsule shell contains gelatin, titanium dioxide (E 171).

PHARMACOLOGICAL GROUP

Combined anti-inflammatory (anti-inflammatory) drugs.

PHARMACOLOGICAL PROPERTIES

Pharmacological.

This drug stimulates the regeneration of cartilage tissue. It has an anti-inflammatory effect at the cellular level, stimulates the synthesis of both endogenous proteoglycans and endogenous hyaluronic acid, reduces the catabolic activity of chondrocytes by inhibiting some enzymes that destroy cartilage, such as collagenase, elastase, proteoglykinase, phospholipase-A2, N-acetylglycosaminidase, etc. , and also inhibits the formation of other substances that can damage cartilage tissue (in vitro), such as superoxide radicals; activity of lysosomal enzymes.

Chondroitin and glucosamine are effective in patients with osteoarthritis.

Chondroitin is one of the main elements of cartilage. It reduces the activity of the inflammatory process in the early stages and thus slows down the degeneration of cartilage tissue. Helps reduce pain, improve joint function and reduce the need for NSAIDs for osteoarthritis of the knee and hip joints.

Glucosamine is physiologically present in the human body and has chondroprotective properties. In vitro and in vivo studies have shown that glucosamine hydrochloride stimulates the synthesis of physiological glycosaminoglycans and proteoglycans by chondrocytes and the synthesis of hyaluronic acid by synoviocytes.

Ibuprofen has antipyretic, analgesic and anti-inflammatory effects. The mechanism of action is associated with non-selective blocking of cyclooxygenase (COX) types 1 and 2 (the main enzyme in the metabolism of arachidonic acid), which leads to a decrease in the synthesis of prostaglandins, a decrease in their concentration in the cerebrospinal fluid and a weakening of the excitation of the thermoregulatory center. Reduces morning stiffness, helps increase range of motion in joints and spine.

The combined use of glucosamine and ibuprofen leads to an increase in the level of analgesic activity of the latter.

Pharmacokinetics.

After a single dose of a therapeutic dose, the maximum level of chondroitin sulfate in the blood plasma is achieved after 3-4 hours. The bioavailability of the dose that was administered orally is 12%.

In the blood, 85% of chondroitin and its depolymerized derivatives are bound to several plasma proteins.

At least 90% of a dose of chondroitin is first metabolized by lysosomal phosphatases, after which it is depolymerized by hyaluronidase, β-glucuronidase and β-N-acetylhexosaminidase in the liver, kidneys and other organs.

Chondroitin and its depolymerized derivatives are eliminated primarily by renal excretion. The half-life ranges from 5 to 15 hours.

After oral administration, glucosamine hydrochloride is rapidly and almost completely absorbed from the intestine. The pharmacokinetics of glucosamine is linear when used in doses up to 1500 mg 1 time per day, and high doses will not lead to a proportionally higher increase in the maximum concentration of glucosamine.

More than 25% of the taken dose of glucosamine passes from the blood plasma into the cartilage tissue and synovial joint membrane.

According to the first pass effect in the liver, more than 70% of glucosamine is metabolized to urea, carbon dioxide and water.

It is excreted unchanged mainly by the kidneys in urine and partially in feces. The half-life is 68 hours.

After oral administration, ibuprofen is almost completely absorbed from the gastrointestinal tract. Concomitant food intake delays absorption. Ibuprofen is metabolized in the liver (90%). The half-life is 2-3 hours. 80% of the dose is excreted in the urine, mainly in the form of metabolites.

INDICATIONS FOR USE

Treatment of pain in primary and secondary osteoarthritis of the joints of the limbs and intervertebral discs.

METHOD OF APPLICATION AND DOSES

The drug should be taken after meals with a glass of water.

Adults take 2 capsules 3 times a day.

Do not exceed the maximum daily dose of 12 capsules (1.2 g ibuprofen).

The duration of treatment at the recommended dose should not exceed 20 days. After the pain disappears, the patient can continue treatment with Artiflex Plus tablets.

CONTRAINDICATIONS

This medicine is contraindicated in the following cases:

• hypersensitivity to the active substances or other components of the drug
• a history of allergic reactions (such as bronchospasm, asthma, rhinitis or skin rashes, angioedema, urticaria associated with the use of acetylsalicylic acid or other NSAIDs);
• history of gastrointestinal bleeding or perforation after using NSAIDs
• gastric ulcer / bleeding currently or in history (two or more clear episodes of exacerbation of peptic ulcer and bleeding)
• optic nerve diseases;
• hematopoiesis disorder;
• severe renal, cardiac or liver failure
• phenylketonuria;
• cerebrovascular or other bleeding
• diabetes
• tendency to bleed;
• thrombophlebitis.

The use of the drug simultaneously with other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, is contraindicated.

INTERACTIONS WITH OTHER MEDICINES AND OTHER TYPES OF INTERACTIONS

Medicines, when used simultaneously with the drug Artiflex Ultra, capsules, an interaction may occur

Ibuprofen

Such combinations with ibuprofen should be avoided.

Acetylsalicylic acid

May increase the risk of side effects. Allowed provided that the dose of acetylsalicylic acid not exceeding 75 mg per day was prescribed by a doctor.

Other NSAIDs, including selective COX-2 inhibitors

The risk of erosive and ulcerative lesions and gastrointestinal bleeding increases (see Section “Contraindications”).

The following combinations with ibuprofen should be used with caution:

Cyclosporine

The risk of nephrotoxicity may increase.

Lithium

The level of lithium in the blood plasma increases.

Methotrexate at a dose of 15 mg/week or higher

The concentration of methotrexate increases and the risk of toxic effects of methotrexate increases.

Anticoagulants

NSAIDs may enhance the effects of anticoagulants such as warfarin.

Corticosteroids

Increased risk of gastrointestinal bleeding or ulceration.

Antihypertensives and diuretics

NSAIDs may reduce the therapeutic effect of these drugs.

In some patients with impaired renal function (eg, dehydrated patients or elderly patients with impaired renal function), concomitant use of ACE inhibitors (ACE inhibitors) or angiotensin II antagonists and agents that inhibit COX may cause further deterioration of renal function, including possible renal failure, potentially reversible. The possibility of such an interaction should be considered in patients taking coxibs concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, this combination should be used with caution, especially in elderly patients. Patients should receive adequate fluids and consideration should be given to monitoring renal function during the initiation of concomitant treatment and periodically thereafter. Diuretics may increase the risk of NSAID nephrotoxicity.

Antiplatelet drugs and selective serotonin reuptake inhibitors

The risk of gastrointestinal bleeding increases.

Cardiac glycosides

NSAIDs can worsen heart failure, reduce glomerular filtration rate, and increase the level of glycosides in the blood.

Zidovudine

When NSAIDs are taken concomitantly with zidovudine, the risk of hematological toxicity increases. There is evidence of an increased risk of hemarthrosis and hematoma in HIV-infected patients receiving concomitant treatment with zidovudine and ibuprofen.

Mifepristone

NSAIDs are not used earlier than 8-12 days after using mifepristone, as they reduce its effectiveness.

Tacrolimus

There may be an increased risk of nephrotoxicity with concomitant use of NSAIDs and tacrolimus.

Potassium-sparing diuretics

Hyperkalemia may occur.

Alcohol

Increased risk of gastrointestinal damage and increased bleeding time.

Quinolone antibiotics

Concomitant use of NSAIDs and quinolone antibiotics may increase the risk of seizures.

Sulfonylureas and phenytoin

The effect of the drugs may be enhanced.

Tetracycline

The absorption of tetracycline from the gastrointestinal tract increases.

Penicillin

The absorption of penicillin is reduced.

Chloramphenicol

The absorption of chloramphenicol is reduced.

Cyclosporine

May affect cyclosporine blood concentrations.

The physicochemical and pharmacokinetic properties of chondroitin and glucosamine indicate a low potential for interactions; specific interaction studies have not been conducted. Chondroitin and glucosamine are compatible with NSAIDs.

It has been recorded that with the simultaneous use of glucosamine and warfarin, the effect of the latter may be enhanced and bleeding may develop. Therefore, during simultaneous use it is necessary to monitor blood coagulation parameters.

APPLICATION FEATURES

Avoid using Artiflex Ultra concomitantly with other NSAIDs, including selective COX-2 inhibitors, due to the increased risk of ulcers or bleeding, as well as other adverse reactions. Adverse reactions can be minimized by taking the lowest effective dose for the shortest amount of time necessary to control symptoms.

Gastrointestinal bleeding, ulceration or perforation, which may be fatal, with or without prior symptoms, has been reported for all NSAIDs at any time during treatment, regardless of a history of severe gastrointestinal complications.

The risk of gastrointestinal bleeding, ulceration or perforation increases with increasing doses of NSAIDs, with a history of ulcers, including those complicated by bleeding or perforation, and in elderly patients. Such patients should begin treatment with the lowest available dose. Combination treatment with protective drugs (particularly misoprostol or proton pump inhibitors) should be considered in these patients, as should patients who require concomitant use of low doses of acetylsalicylic acid or other drugs that may increase gastrointestinal risk.

Patients with a history of gastrointestinal disorders, especially elderly patients, should report any unusual abdominal symptoms (in particular gastrointestinal bleeding) to the physician, especially in the early stages of treatment. Caution should be exercised when treating patients concomitantly receiving drugs that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors, and antiplatelet agents such as acetylsalicylic acid.

If patients receiving ibuprofen develop gastrointestinal bleeding or ulceration, treatment should be discontinued.

NSAIDs should be used with caution in patients with a history of ulcerative colitis or Crohn's disease, as their condition may worsen.

If acetylsalicylic acid is used to suppress platelet aggregation, you should consult your doctor before starting treatment with Artiflex Ultra.

There is evidence that drugs that inhibit COX/prostaglandin synthesis may impair female fertility through effects on ovulation. This can be corrected by stopping these medications.

The use of ibuprofen, especially in high doses (2400 mg/day) during long-term treatment, may be associated with a slight increase in the risk of arterial thrombotic complications (eg myocardial infarction or stroke). Low doses of ibuprofen (≤ 1200 mg/day) are not associated with an increased risk of myocardial infarction.

For patients with uncontrolled hypertension, congestive heart failure, diagnosed coronary artery disease, peripheral arterial disease and/or cerebrovascular disease, long-term treatment should only be prescribed by a physician after careful analysis. In patients with significant risk factors for cardiovascular complications (such as hypertension, hyperlipidemia, diabetes mellitus, smoking), long-term treatment with NSAIDs should be prescribed only after careful consideration.

Very rarely, severe skin reactions, some fatal, have been reported with NSAIDs, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis. Obviously, the highest risk of such reactions is in the early stages of treatment: the onset of such a reaction in most cases was observed during the first month of treatment. Treatment with ibuprofen should be discontinued at the first sign of skin rash, mucosal ulceration or any other sign of hypersensitivity.

Ibuprofen may cause bronchospasm and asthma attacks or other hypersensitivity reactions. Risk factors for such reactions include pre-existing asthma, hay fever, nasal polyps, sensitivity to acetylsalicylic acid or chronic respiratory diseases. This also applies to patients who experience allergic reactions to ibuprofen or other NSAIDs (in particular skin reactions, itching, urticaria).

It is not recommended to drink alcohol during treatment with Artiflex Ultra.

Use with caution in patients with:

• systemic lupus erythematosus and systemic connective tissue diseases - increased risk of aseptic meningitis;
• history of arterial hypertension and/or heart failure, which were accompanied by fluid retention and edema when using NSAIDs
• impaired renal and/or liver function; liver dysfunction increases the risk of renal toxicity and injury, as well as severe and potentially fatal liver reactions. For patients with liver or kidney disease, additional examinations are recommended before starting treatment: monitoring liver and kidney function and peripheral blood tests.

Long-term use of NSAIDs can lead to a dose-dependent decrease in prostaglandin synthesis and provoke the development of renal failure. Patients taking diuretics are at high risk; patients with impaired liver function, kidney function and / or cardiac disorders; elderly patients.

Features of the use of glucosamine sulfate and chondroitin sulfate

The drug should not be used in patients with hypersensitivity (allergy) to seafood.

An exacerbation of asthma symptoms is possible in patients with a history of bronchial asthma after starting treatment with glucosamine.

Rarely, edema and/or water retention in the body have been observed in patients with heart and/or renal failure. This may be due to the osmotic effect of chondroitin sulfate.

You should contact your doctor if your symptoms worsen after starting this drug.

Use during pregnancy or breastfeeding. Although the use of drugs containing ibuprofen is contraindicated only during the third trimester of pregnancy, there are no clinical data regarding the effectiveness and safety of glucosamine sulfate during pregnancy or lactation. Therefore, it should not be used during these periods.

ABILITY TO INFLUENCE REACTION SPEED WHEN DRIVING VEHICLES OR OTHER MECHANISMS

The patient should monitor changes in his reaction speed before driving or operating machinery. If any adverse effects from the nervous system are detected, you should stop driving vehicles or using other mechanisms.

CHILDREN

There is no experience with the use of the drug in children (under 18 years of age).

OVERDOSE

In case of overdose, abdominal pain, nausea, vomiting, diarrhea, gastrointestinal bleeding, dizziness, headache, sleep disturbance and tinnitus may occur. In severe cases, symptoms from the nervous system may occur: drowsiness, lethargy, occasionally - agitation and disorientation, loss of consciousness or coma, possible arterial hypertension, arterial hypotension, impaired liver and kidney function or hepatonecrosis, acute renal failure, rhabdomyolysis and hypothermia; respiratory failure and cyanosis. Occasionally, in case of overdose, convulsions are observed. In patients with bronchial asthma, exacerbation of asthma is possible. In severe overdose, metabolic acidosis (including renal tubular acidosis) and hypokalemia may develop, and the prothrombin time/INR may be prolonged, probably due to interactions with coagulation factors.

Treatment is symptomatic, aimed at ensuring the vital functions of the body, including ensuring airway patency, and normalizing the condition. It is recommended that gastric lavage and oral administration of activated carbon be performed within 1:00 after administration of a potentially toxic dose of the drug (more than 400 mg/kg) and hospitalization in the toxicology department. At the inpatient stage, infusion therapy, forced diuresis, and symptomatic treatment are used. There are no special antidotes. Frequent or prolonged seizures should be treated with intravenous diazepam or lorazepam. For bronchial asthma, bronchodilators should be used.

ADVERSE REACTIONS

Most side effects after using the drug Artiflex Ultra are caused by ibuprofen and are dose-dependent. Since the recommended single dose of ibuprofen is moderate, and the usual daily dose of Artiflex Ultra (600 mg) is significantly lower than its maximum daily dose (1200 mg), it is unlikely that any side effects will be observed if the drug is used as recommended by dosage.

From the gastrointestinal tract. Abdominal pain, dyspepsia, nausea, diarrhea, flatulence, constipation and vomiting. Possible heartburn, ulcerative stomatitis, peptic ulcers, ground, hematemesis, gastritis, perforation or gastrointestinal bleeding, in some cases can be fatal, especially in elderly patients. In rare cases, exacerbation of ulcerative colitis and Crohn's disease has been reported.

From the nervous system. Headache, aseptic meningitis (single cases have been reported). Dizziness, drowsiness, paresthesia, general weakness and increased fatigue may occur. Only with long-term use - depression, hallucinations, confusion, tinnitus.

In patients with autoimmune disorders (in particular, systemic lupus erythematosus, systemic connective tissue diseases), isolated symptoms of aseptic meningitis were observed when treated with ibuprofen, namely: stiff neck, headache, nausea, vomiting, high fever or disorientation.

From the urinary system. There are reports of acute renal failure and papilonecrosis, especially with long-term use, in combination with an increase in serum urea levels and edema. Ibuprofen can cause interstitial nephritis, nephrotic syndrome, nephrotoxicity.

From the digestive system. Liver disorders are possible, especially with long-term use, such as hepatitis and jaundice.

From the blood and lymphatic system. Disorders of the hematopoietic system (anemia, neutropenia, aplastic anemia, hemolytic anemia, eosinophilia, decreased hematocrit and hemoglobin levels, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis). The first signs are high fever, sore throat, mouth ulcers, flu-like symptoms, severe exhaustion, unexplained bleeding and bruising. Reversible platelet aggregation, alveolitis, pulmonary eosinophilia.

From the skin and subcutaneous tissue. In rare cases, severe skin reactions such as erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis may occur. Peeling of the skin, alopecia, photosensitivity, hyperemia, dermatitis, and eczema may occur.

From the immune system. Allergic reactions, including severe hypersensitivity reactions, swelling of the face, tongue and larynx, shortness of breath, angioedema, anaphylactic shock, anaphylaxis, urticaria, itching, rash, airway reactivity, including bronchial asthma, exacerbation of asthma, bronchospasm.

From the cardiovascular system and cerebral circulation. Edema, hypertension, heart failure, tachycardia, and palpitations have been reported during treatment with NSAIDs. Long-term use of ibuprofen in high doses (2400 mg/day) may lead to a slight increase in the risk of arterial thrombosis (myocardial infarction or stroke). Complications from cerebral circulation are possible.

From the organs of vision. With long-term use - blurred vision, optic neuritis.

Laboratory results. Increased ALT level, increased blood creatinine level, increased AST level, increased blood urea level, increased blood bilirubin level.

Other. Changes in the endocrine system and metabolism, decreased appetite, dry mucous membranes of the eyes and mouth, rhinitis, hearing loss.

Taking Artiflex Ultra should be stopped if any adverse reaction occurs and consult a doctor immediately.

BEST BEFORE DATE

2 years.

STORAGE CONDITIONS

Store in original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.

VACATION CATEGORY

Over the counter.

Analogs

If necessary, Artiflex can be replaced with an analogue drug. Listed below are medications with similar compositions available in Russian and/or Ukrainian pharmacies:

Reviews

Reviews about the effectiveness of Artiflex are positive. Artiflex is often prescribed for degenerative-dystrophic pathologies of the spinal column and joints.

Patients praise the effectiveness of the drug, the duration of its action (the effect lasts for several months), and the almost complete absence of side effects.

The only negative point is the high cost of the medication.

If you go to the end of the article, you can see people's reviews about Artiflex.

There (if desired) you can share your opinion about the cream and powder.

By doing this you will provide an invaluable service to other site visitors.

Artiflex Plus tablets 1000 mg No. 60